HPV Testing and Pap Test Market Size Worth $6.39 Billion By 2028 | CAGR: 15.9%

The global HPV testing and Pap test market size is expected to reach USD 6.39 billion by 2028 according to a new study by Polaris Market Research. The report “HPV Testing and Pap Test Market Share, Size, Trends, Industry Analysis Report, By Test (Pap, HPV); By Application (Cervical Cancer Screening, Vaginal Cancer Screening); By Product (Instruments, Consumables, Services); By Technology (PCR, Immunodiagnostics, Other Technologies); By Region; Segment Forecast, 2021 - 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing incidence of cervical cancer has increased the need for screening procedures that are expected to be the main driving factor. The emergence of new technology is expected to drive the growth of the market further. There is a rapid increase in the incidence of cervical cancer globally.

New technologies are being developed to improve the sensitivity of the examinations. Recently, point-of-care HPV testing device based on artificial intelligence has been developed by researchers.

This technology involves tiny beads, and when it comes to contact with HPV, it will form a diamond shape that can be detected with microscopes or a mobile phone app developed through machine learning.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/hpv-testing-and-pap-test-market/request-for-sample

Many new examinations are being launched in the market due to the increasing need to diagnose cervical cancer. In 2021, Nguyen Biosciences launched molecular diagnostics technology for cervical cancer screening in India. This solution can detect the disease before the manifestation of symptoms. Abris raised USD 2.4 Billion to expand the commercialization of its lateral flow examination that uses a biomarker for HPV16 and can provide fast results in 20 minutes.

Market Participants such as Becton, Qiagen, Dickinson and Company, Quest Diagnostics, Hologic, Inc., Roche Ltd, Femasys, Inc., Abbott Laboratories, NURX, Inc., Arbor Vita Corporation, Seegene, Inc., Thermo Fisher Scientific, Inc., and BioMérieux SA., are some of the key players operating in the global market.

Polaris Marker Research has segmented the HPV testing and Pap test market report on the basis of test, application, product, technology, end-use, and region:

HPV Testing and Pap Test, Test Outlook (Revenue - USD Billion, 2016 - 2028)

• Pap
• HPV

HPV Testing and Pap Test, Application Outlook (Revenue - USD Billion, 2016 - 2028)

• Cervical Cancer Screening
• Vaginal Cancer Screening

HPV Testing and Pap Test, Product Outlook (Revenue - USD Billion, 2016 - 2028)

• Instruments
• Consumables
• Services

HPV Testing and Pap Test, Technology Outlook (Revenue - USD Billion, 2016 - 2028)

• PCR
• Immunodiagnostics
• Other Technologies

HPV Testing and Pap Test, Regional Outlook (Revenue - USD Billion, 2016 - 2028)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Austria
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa